Varma Poornima, Falconer Julianne, Aga Ahmad, Prince H Miles, Pianko Stephen
a Department of Gastroenterology , Cabrini Health , Malvern , Australia.
b Department of Haematology , Cabrini Health , Malvern , Australia.
Scand J Gastroenterol. 2017 May;52(5):606-608. doi: 10.1080/00365521.2017.1280530. Epub 2017 Jan 27.
The use of rituximab has significantly improved outcomes in patients with haematological malignancies and autoimmune disease. There are reports of rituximab-associated ulcerative colitis; however, we report for the first time, two cases of rituximab-induced Crohn's disease in elderly patients treated for lymphoma. Both patients had evidence of inflammation, ulceration, and granulomas consistent with Crohn's disease, and responded well to immunosuppression. The association of rituximab and ileocolitis suggests a protective effect of CD20 + lymphocytes in the gut, and implicates their depletion to the development and exacerbation of inflammatory bowel disease.
利妥昔单抗的使用显著改善了血液系统恶性肿瘤和自身免疫性疾病患者的治疗效果。有关于利妥昔单抗相关溃疡性结肠炎的报道；然而，我们首次报告了两例在接受淋巴瘤治疗的老年患者中由利妥昔单抗诱发的克罗恩病。两名患者均有与克罗恩病相符的炎症、溃疡和肉芽肿证据，且对免疫抑制治疗反应良好。利妥昔单抗与回结肠炎症的关联提示肠道中CD20+淋巴细胞具有保护作用，并表明其耗竭与炎症性肠病的发生和加重有关。
